Belatacept Medicine 08 December 2020 Extended indication Extension of indication to include the use of belatacept in conversion from a calcinerin inhibitor -based regimen to a belatacept-based regimen post transplantation. Therapeutic value No judgement Total cost Registration phase Registration application pending Product Active substance Belatacept Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Other chronic immune diseases Extended indication Extension of indication to include the use of belatacept in conversion from a calcinerin inhibitor -based regimen to a belatacept-based regimen post transplantation. Current proprietary name Already available biosimilars / generics Proprietary name Nulojix Manufacturer BMS Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date August 2020 Expected Registration June 2021 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks NULOJIX, 250 mg POEDER VOOR OPLOSSING VOOR INFUSIE 250MG € 483,04. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks